Navigation Links
Mindray to Launch New DC-T6 Ultrasound System at RSNA
Date:11/28/2011

MAHWAH, N.J., Nov. 28, 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, today announced that it will introduce the new DC-T6 ultrasound system at the annual Radiological Society of North America conference to be held November 27 -- December 1, 2011 in Chicago. The new system is an affordable, fully featured, high-performance imaging solution with a user-friendly, compact mobile design.  

"The DC-T6 offers numerous advanced capabilities while providing exceptional ergonomic solutions for user comfort," said Michael Thompson, Vice President of Ultrasound Sales, Mindray North America. "Innovative and clinical-relevant features are paired with superior imaging performance to maximize diagnostic confidence. It is designed primarily for vascular applications but also covers a broad range of clinical specialties."

The DC-T6 system features a high-resolution, 15-inch TFT monitor as well as a swivel and height-adjustable control panel. The system's embedded battery, iPower™, provides up to two hours of interruptible scanning when AC power is not available. Its octal beam formation technology strikes a balance between temporal and spatial resolution while the iClear™ speckle reduction technology improves contrast resolution without compromising spatial resolution. The system offers real-time 4D and panoramic imaging. Additional features include Tissue Doppler imaging (TDI) with quantitative analysis, automatic M-Mode, improved cystic clarity and better signal-to-noise ratio as well as fast and efficient storage, review and management of image data using the iStation™ technology.

The DC-7 Ultrasound EnhancementsThe company will also be showcasing enhancements for its DC-7 ultrasound system that includes an iPage 3D
'/>"/>

SOURCE Mindray Medical International Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Mindray Files Annual Report on Form 20-F with U.S. Securities and Exchange Commission
2. Mindray Medical to Present at J.P. Morgan China Conference 2010
3. Mindray Medical Provides Mid-Year Update on Product Development
4. Mindray to Report Second Quarter 2010 Financial Results on August 9, 2010
5. Mindray to Attend the 2010 American Association for Clinical Chemistry Conference
6. Mindray Launches New Premium M7 Portable Ultrasound System in U.S.
7. Mindray Medical to Present at the Goldman Sachs 7th Annual European Medtech and Healthcare Services Conference
8. Mindray Medical to Present at the Morgan Stanley Global Healthcare Conference
9. /C O R R E C T I O N - Mindray Medical International Limited /
10. Mindray Appoints Mr. Minghe Cheng as Chief Strategic Officer
11. Mindray Medical to Exhibit New Products at 64th China International Medical Equipment Fair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Kansas blocked the sale of ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com announces ... in its catalogue: The Impact of ... http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html ... 3590) is complex legislation that affects virtually every ... provisions are beginning to take effect now. IVD ...
(Date:8/20/2014)... 20, 2014 Research and Markets ... "Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and ... report to their offering. A ... and geography) - Size, Share, Global Trends, Company ... and Forecast, 2013 - 2020", suggests that the ...
Breaking Medicine Technology:Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Research Report, 2013 - 2020 2
... 2012  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today ... 2012.  For the first quarter of 2012, the Company reported ... compared with a net income of $2.9 million, or $0.05 ... $3.8 million change in operating results is primarily due to ...
... Janssen Research & Development, LLC, (Janssen), announced today ... to the U.S. Food and Drug Administration (FDA) seeking ... an oral anticoagulant, to treat patients with deep vein ... recurrent venous thromboembolism (VTE). These submissions are ...
Cached Medicine Technology:Neurocrine Biosciences Reports First Quarter 2012 Results 2Neurocrine Biosciences Reports First Quarter 2012 Results 3Neurocrine Biosciences Reports First Quarter 2012 Results 4Neurocrine Biosciences Reports First Quarter 2012 Results 5Neurocrine Biosciences Reports First Quarter 2012 Results 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 2Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 3Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 4Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 5Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 7Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 8
(Date:8/20/2014)... Today, Zane Benefits, the #1 ... a new eBook, Affordable Care Act 101. , ... feel uncertain about how the ACA impacts their ... line. , The new eBook outlines key ACA ... their upcoming health insurance decisions. , Read the ...
(Date:8/20/2014)... Locating rates for insurance packages will now be an ... new source of term life insurance providers has been added ... 50 states at http://quotespros.com/life-insurance.html . , The database ... available for the public to find out the exact annual ... quotations that are available are good through the rest of ...
(Date:8/20/2014)... group representing U.S. obstetricians is calling for all pregnant ... the American College of Obstetricians and Gynecologists (ACOG), several ... and effectiveness of flu vaccination during pregnancy. "The ... dangerous to pregnant women, as it can cause pneumonia, ... of the college,s Immunization Expert Work Group, explained in ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, ... a group of rhesus monkeys from deadly Marburg virus, a ... 90 percent of those it infects, researchers report. The ... virus, even when it was given three days after infection, ... Science Translational Medicine . This is the first ...
(Date:8/20/2014)... Line: Less than 42 percent of women underwent ... the factors associated with foregoing reconstruction included being ... older. , Author: Monica Morrow, M.D., of the ... colleagues. , Background: The Women,s Health and Cancer ... breast reconstruction following a mastectomy. Still, most women ...
Breaking Medicine News(10 mins):Health News:Term Life Insurance Price Database Now Helps Quote Prices for Adults in 50 States Online 2Health News:All Pregnant Women Need Flu Shot: Ob/Gyn Group 2Health News:Drug for Ebola-Like Virus Shows Promise in Monkeys 2Health News:Drug for Ebola-Like Virus Shows Promise in Monkeys 3Health News:Patient perspectives on breast reconstruction following mastectomy 2
... By Tobacco Advertising and Find It,Easy to Buy Cigarettes, ... against tobacco on April 2 as they join thousands ... Day, sponsored by the Campaign,for Tobacco-Free Kids. Hundreds of ... local events, go to http://www.kickbuttsday.org/events )., This ...
... March 27 The Richard B. and,Lynne V. ... John Ray have joined the Institute,s Board of ... for the Institute., "Mary Matalin,s experience in ... to the Institute as we build our organization ...
... Calif., March 27 Clarient, Inc.,(Nasdaq: CLRT ), ... the pharmaceutical industry, today announced,that it is scheduled to ... Co.,9th Annual Las Vegas Investor Conference at 4:00 p.m. ... conference is being held at the Palms,Casino Resort April ...
... Now Have Choices and Flexibility ... Typically Available on Larger Plans, NEW YORK, ... to,nine employees can now choose from a wider selection of ... larger,companies., The Guardian Life Insurance Company of America (Guardian), ...
... a mental rigidity that keeps them from folding their ... form of mental rigidity that leads to compulsive behavior ... luck even when they,re on a losing streak, a ... causes compulsive gambling, but it,s been suggested that environmental ...
... CHICAGO, IL MARCH 27, 2008 The Cardiovascular ... meta-analysis to date comparing mortality rates for drug-eluting stents ... Stent Revolution VII meeting tomorrow evening in Chicago. ... studieswas performed by a team of researchers led by ...
Cached Medicine News:Health News:D.C. Kids 'Kick Butts' on April 2 2Health News:D.C. Kids 'Kick Butts' on April 2 3Health News:Mary Matalin and John Ray Join the Cheney Cardiovascular Institute Board of Directors 2Health News:Clarient to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference 2Health News:Guardian Expands Dental Benefit Options Helps Small Business Owners Lower Insurance Cost 2Health News:Guardian Expands Dental Benefit Options Helps Small Business Owners Lower Insurance Cost 3Health News:Compulsive Gamblers Don't Learn From Their Mistakes 2Health News:Largest ever analysis of DES data demonstrates safety, efficacy in on-and-off-label use 2
Bone Curette, 170 mm...
Bone Currettes...
Kevorkian Endocervical Curette is a stainless-steel curette with a basket. It is narrow tipped for sampling without dilation....
...
Medicine Products: